Article

Repurposing azacitidine and carboplatin to prime for anti-PDL1 re-challenge of immunotherapy-resistant melanoma

2022-02-04

Abstract excerpt

Drug repurposing offers the opportunity for approved chemotherapy agents to be used to re-establish sensitivity to immune checkpoint blockade (ICB) therapy. Here we investigated the clinical and translational aspects of an early phase II study of azacitidine and carboplatin priming for anti-PDL1 immunotherapy (Avelumab) in patients with advanced ICB-resistant melanoma. 20 participants with ICB resistant metastatic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a10f2d45-678c-5524-8025-ab32d37a5e01
DOI: 10.1101/2022.02.03.22270286

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 9 closest

Repurposing azacitidine and carboplatin to prime for anti-PDL1 re-challenge of immunotherapy-resistant melanomaDOI 10.1101/2022.02.03.22270286Read

Reduction of soluble PD-L1 by plasma exchange and radiation therapy in patients with refractory melanoma re-sensitizes to immunotherapy.Semantic proximity Read

Cautious Addition of Targeted Therapy to PD-1 Inhibitors after Initial Progression of BRAF Mutant Metastatic Melanoma on Checkpoint Inhibitor TherapySemantic proximity Read

Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade.Semantic proximity Read

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.Semantic proximity Read

LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 TrialsSemantic proximity Read

Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancerSemantic proximity Read

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.Semantic proximity Read

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.Semantic proximity Read

Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break.Semantic proximity Read